nach oben

DGNeurologie

Erschienen in:

10.08.2020 | HIV | CME Zertifizierte Fortbildung

Progressive multifokale Leukenzephalopathie – ein Update

verfasst von: Dr. T. Rempe, F. Leypoldt, O. Jansen, D. Berg, T. Bartsch

Erschienen in: DGNeurologie | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die progressive multifokale Leukenzephalopathie (PML) ist eine meist im Rahmen einer Immunsuppression durch das JC-Polyomavirus (JCV) ausgelöste Erkrankung des Zentralnervensystems. Aufgrund der Anwendung von Immunmodulatoren und -suppressiva bei Autoimmunerkrankungen haben sich Risikospektrum und Krankheitsverlauf verändert. Mit der Identifikation atypischer zerebraler JCV-Infektionen wie der JCV Körnerzellneuronopathie hat sich das klinische Spektrum erweitert. Es wurden neue Risikostratifizierungsstrategien eingeführt, diagnostische Hilfsmittel wie der JCV-Antikörperindex validiert und bildgebende Marker zur Früherkennung der PML, des entzündlichen Immunrekonstitutionssyndroms sowie zur Differenzierung von Multiple-Sklerose-Läsionen entwickelt. Zur Diagnosestellung wurden spezifische diagnostische Kriterien und ein diagnostischer Algorithmus entworfen. Die Diagnose einer PML sollte bei allen immunsupprimierten Patienten mit progredienten neurologischen Symptomen bedacht werden.

Tan CS, Ellis LC, Wuthrich C et al (2010) JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 84:9200–9209PubMedPubMedCentral

Wollebo HS, White MK, Gordon J et al (2015) Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560–570PubMedPubMedCentral

Hirsch HH, Kardas P, Kranz D et al (2013) The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 121:685–727PubMed

Kean JM, Rao S, Wang M et al (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363PubMedPubMedCentral

Knowles WA, Pipkin P, Andrews N et al (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115–123PubMed

Bartsch T, Rempe T, Leypoldt F et al (2019) The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur J Neurol 26:566–e541PubMed

Shah R, Bag AK, Chapman PR et al (2010) Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 65:431–439PubMed

Jelcic I, Jelcic I, Faigle W et al (2015) Immunology of progressive multifocal leukoencephalopathy. J Neurovirol 21:614–622PubMed

Power C, Gladden JG, Halliday W et al (2000) AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54:743–746PubMed

10.

Amend KL, Turnbull B, Foskett N et al (2010) Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 75:1326–1332PubMed

11.

Engsig FN, Hansen AB, Omland LH et al (2009) Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 199:77–83PubMed

12.

Khanna N, Elzi L, Mueller NJ et al (2009) Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 48:1459–1466PubMed

13.

Jamilloux Y, Neel A, Lecouffe-Desprets M et al (2014) Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology 82:1307–1313PubMed

14.

Clifford DB, De Luca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438–446PubMed

15.

Biogen TYSABRI® (natalizumab): PML Incidence in Patients Receiving TYSABRI. Antwortschreiben: Anfragenummer M-TY-US-00160, 17. Juni 2020

16.

Novartis Pharmaceuticals Corporation. GILENYA – Progressive Multifocal Leukoencephalopathy. Antwortschreiben: Anfragenummer I-04416897, 9. Juli 2020

17.

Biogen TECFIDERA® (dimethyl fumarate): Progressive Multifocal Leukoencephalopathy Summary. Antwortschreiben: Anfragenummer M-TE-US-00229, 29. Apr. 2020

18.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT et al (2017) Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 264:1155–1164PubMed

19.

Genentech (2018) Ocrevus and progressive multifocal leukoencephalopathy (PML). US-18-035526

20.

Gheuens S, Pierone G, Peeters P et al (2010) Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 81:247–254PubMed

21.

Sipeki N, Antal-Szalmas P, Lakatos PL et al (2014) Immune dysfunction in cirrhosis. World J Gastroenterol 20:2564–2577PubMedPubMedCentral

22.

Kato S, Chmielewski M, Honda H et al (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3:1526–1533PubMedPubMedCentral

23.

Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880PubMed

24.

Sorensen PS, Bertolotto A, Edan G et al (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18:143–152PubMed

25.

Ryerson LZ, Foley J, Chang I et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93:e1452–e1462PubMedPubMedCentral

26.

Plavina T, Subramanyam M, Bloomgren G et al (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802–812PubMed

27.

Koralnik IJ (2014) Finger pointing to JC virus: a tale of two indexes. Ann Neurol 76:789–791PubMedPubMedCentral

28.

Rempe T, Carlson A, Miravalle A et al (2020) Ocrelizumab treatment is not associated with an increase in anti-JCV antibody index. Neurology 94:295

29.

Baber U, Bouley A, Egnor E et al (2018) Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients. J Neurol 265:2342–2345PubMed

30.

Farley S, Gottesman MH, Friedman-Urevich S et al (2019) Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate. Surg Neurol Int 10:59PubMedPubMedCentral

31.

Biogen (2015) Tecfidera (Dimethylfumarat): Neue Maßnahmen zur Senkung des Risikos einer PML – vermehrte Überwachung und Absetzen der Therapie. Rote-Hand-Brief, 23. Nov 2015

32.

Vorstand des Ärztlichen Beirates der Deutschen Multiple Sklerose Gesellschaft (DMSG), Bundesverband e. V., Vorstand des Krankheitsbezogenen Kompetenznetzes Multiple Sklerose (KKNMS) (2015) Multiple Sklerose: Maßnahmen zur Minimierung des PML-Risikos unter Dimethylfumarat (Tecfidera®). DMSG, KKNMS, München/Hannover (Stellungnahme)

33.

Bartsch T, Rempe T, Wrede A et al (2015) Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 78:501–514PubMedPubMedCentral

34.

Maas RP, Muller-Hansma AH, Esselink RA et al (2016) Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol 263:2004–2021PubMedPubMedCentral

35.

Lima MA, Drislane FW, Koralnik IJ (2006) Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66:262–264PubMed

36.

Khoury MN, Alsop DC, Agnihotri SP et al (2014) Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol 75:659–669PubMedPubMedCentral

37.

Wuthrich C, Koralnik IJ (2012) Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 71:54–65PubMedPubMedCentral

38.

Wuthrich C, Dang X, Westmoreland S et al (2009) Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 65:742–748PubMedPubMedCentral

39.

Wattjes MP, Vennegoor A, Steenwijk MD et al (2015) MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 86:793–798PubMed

40.

Yousry TA, Pelletier D, Cadavid D et al (2012) Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72:779–787PubMed

41.

Hodel J, Darchis C, Outteryck O et al (2016) Punctate pattern: a promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology 86:1516–1523PubMed

42.

Wattjes MP, Richert ND, Killestein J et al (2013) The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 19:1826–1840PubMed

43.

Bergui M, Bradac GB, Oguz KK et al (2004) Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 46:22–25PubMed

44.

Cosottini M, Tavarelli C, Del Bono L et al (2008) Diffusion-weighted imaging in patients with progressive multifocal leukoencephalopathy. Eur Radiol 18:1024–1030PubMed

45.

Wijburg MT, Witte BI, Vennegoor A et al (2016) MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry 87:1138–1145PubMed

46.

Sinnecker T, Othman J, Kuhl M et al (2016) Progressive multifocal leukoencephalopathy in a multiple sclerosis patient diagnosed after switching from natalizumab to fingolimod. Case Rep Neurol Med 2016:5876798PubMedPubMedCentral

47.

Berger JR, Pall L, Lanska D et al (1998) Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 4:59–68PubMed

48.

Wattjes MP, Wijburg MT, Van Eijk J et al (2018) Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. J Neurol Neurosurg Psychiatry 89:535–541PubMed

49.

Tan K, Roda R, Ostrow L et al (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72:1458–1464PubMedPubMedCentral

50.

Sainz-De-La-Maza S, Casado JL, Perez-Elias MJ et al (2016) Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy. Eur J Neurol 23:919–925PubMed

51.

Bonham S, Meya DB, Bohjanen PR et al (2008) Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark Med 2:349–361PubMedPubMedCentral

52.

Wattjes MP, Wijburg MT, Vennegoor A et al (2016) Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. Mult Scler 22:1174–1183PubMed

53.

Hoepner R, Ahlbrecht J, Faissner S et al (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 85:1177–1178PubMed

54.

Henry C, Jouan F, De Broucker T (2015) JC virus granule cell neuronopathy: a cause of infectious cerebellar degeneration. J Neurol Sci 354:86–90PubMed

55.

Rempe T, Wang Q, Wu Q et al (2020) PML and GCN with novel mutation flanking VP1 C-terminus in natalizumab extended interval dosing. Neurol Neuroimmunol Neuroinflamm 7:e709PubMedPubMedCentral

56.

Wijburg MT, Van Oosten BW, Murk JL et al (2015) Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. J Neurol 262:65–73PubMed

57.

Wijburg MT, Siepman D, Van Eijk JJ et al (2016) Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. J Neurol. https://doi.org/10.1007/s00415-015-8001-3CrossRefPubMedPubMedCentral

58.

Wuthrich C, Cheng YM, Joseph JT et al (2009) Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 68:15–25PubMedPubMedCentral

59.

Berger JR, Aksamit AJ, Clifford DB et al (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80:1430–1438PubMedPubMedCentral

60.

Agnihotri SP, Wuthrich C, Dang X et al (2014) A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann Neurol 76:140–147PubMedPubMedCentral

61.

Behzad-Behbahani A, Klapper PE, Vallely PJ et al (2003) BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis. Infection 31:374–378PubMed

62.

Blake K, Pillay D, Knowles W et al (1992) JC virus associated meningoencephalitis in an immunocompetent girl. Arch Dis Child 67:956–957PubMedPubMedCentral

63.

Viallard JF, Ellie E, Lazaro E et al (2005) JC virus meningitis in a patient with systemic lupus erythematosus. Lupus 14:964–966PubMed

64.

Marzocchetti A, Di Giambenedetto S, Cingolani A et al (2005) Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 43:4175–4177PubMedPubMedCentral

65.

Wijburg MT, Warnke C, Barkhof F et al (2018) Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2018-318261CrossRefPubMed

66.

Warnke C, Wijburg MT, Hartung HP et al (2017) Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 88:1092–1094PubMed

67.

Dalla Costa G, Martinelli V, Moiola L et al (2019) Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol 85:606–610PubMed

68.

Sahraian MA, Radue EW, Eshaghi A et al (2012) Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 19:1060–1069PubMed

69.

Guggenberger K, Urbach H (2018) MRT-Veränderungen bei Immunmodulation. Nervenarzt 89:945–957PubMed

70.

Pavlovic D, Patera AC, Nyberg F et al (2015) Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 8:255–273PubMedPubMedCentral

71.

Gasnault J, Costagliola D, Hendel-Chavez H et al (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. Plos One 6:e20967PubMedPubMedCentral

72.

Clifford DB (2015) Neurological immune reconstitution inflammatory response: riding the tide of immune recovery. Curr Opin Neurol 28:295–301PubMedPubMedCentral

73.

Scarpazza C, Prosperini L, De Rossi N et al (2017) To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann Neurol 82:697–705PubMed

74.

Landi D, De Rossi N, Zagaglia S et al (2017) No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88:1144–1152PubMed

75.

Jamilloux Y, Kerever S, Ferry T et al (2016) Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clin Drug Investig 36:783–789PubMed

76.

Clifford DB, Nath A, Cinque P et al (2013) A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 19:351–358PubMedPubMedCentral

77.

De Luca A, Ammassari A, Pezzotti P et al (2008) Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22:1759–1767PubMed

78.

Gosert R, Rinaldo CH, Wernli M et al (2011) CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob Agents Chemother 55:2129–2136PubMedPubMedCentral

79.

Patel A, Patel J, Ikwuagwu J (2010) A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 65:2697–2698PubMed

80.

Hall CD, Dafni U, Simpson D et al (1998) Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338:1345–1351PubMed

81.

Dubey D, Zhang Y, Graves D et al (2016) Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. Ther Adv Neurol Disord 9:211–215PubMed

82.

Harel A, Horng S, Gustafson T et al (2018) Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. J Neurovirol. https://doi.org/10.1007/s13365-018-0657-xCrossRefPubMed

83.

Sospedra M, Schippling S, Yousef S et al (2014) Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 59:1588–1592PubMedPubMedCentral

84.

Muftuoglu M, Olson A, Marin D et al (2018) Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med 379:1443–1451PubMedPubMedCentral

85.

Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380:1597–1605PubMed

86.

Berger JR (2009) Steroids for PML-IRIS: a double-edged sword? Neurology 72:1454–1455PubMed

87.

Steiner I, Benninger F (2017) Maraviroc in PML-IRIS: a separate ball game under HIV infection and natalizumab? Neurol Neuroimmunol Neuroinflamm 4:e331PubMedPubMedCentral

88.

Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425–437PubMedPubMedCentral

89.

Dong-Si T, Gheuens S, Gangadharan A et al (2015) Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 21:637–644PubMedPubMedCentral

90.

Dahlhaus S, Hoepner R, Chan A et al (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84:1068–1074PubMedPubMedCentral

91.

Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697–1704PubMed

Titel: Progressive multifokale Leukenzephalopathie – ein Update
verfasst von: Dr. T. Rempe
F. Leypoldt
O. Jansen
D. Berg
T. Bartsch
Publikationsdatum: 10.08.2020
Verlag: Springer Medizin
Schlagwörter: HIV
Multiple Sklerose
Lymphopenie
Natalizumab
Erschienen in: DGNeurologie / Ausgabe 5/2020
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI: https://doi.org/10.1007/s42451-020-00220-7

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Magazin

Koma unklarer Genese: SOP für die Notaufnahme

Wiederkehrende passagere Kopfschmerzen, Schwindel, Sehstörungen und Beinparesen seit 8 Wochen

Rezidivierende Synkopen beim Essen

Malignomrisiko unter MS-Immuntherapien – neue Daten

Wirtschaftliche Unabhängigkeit der ärztlichen Fortbildung